Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$500K Buy
7,430
+4,026
+118% +$268K 0.09% 237
2026
Q1
$214K Buy
+3,404
New +$237K 0.05% 301
2025
Q4
Sell
-26,004
Closed -$1.75M 388
2025
Q3
$1.75M Buy
26,004
+10,040
+63% +$795K 0.33% 55
2025
Q2
$1.39M Sell
15,964
-421
-3% -$33K 0.24% 94
2025
Q1
$1.12M Buy
+16,385
New +$1.34M 0.22% 108

Other funds holding DXCM

111 Capital's DXCM Position: Q2 2026 in Review

111 Capital increased its DexCom (DXCM) stake by 118% in Q2 2026, buying an estimated $268K and bringing the position to 7,430 shares worth $500K. The position accounts for 0.09% of the portfolio, ranked #237.

111 Capital first reported a position in DXCM in Q1 2025 and has held it in 5 quarters since. The position peaked at $1.75M in Q3 2025. 968 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

  • 111 Capital held 7,430 shares of DexCom worth $500K as of Q2 2026.
  • 111 Capital bought 4,026 DexCom shares in Q2 2026, an estimated $268K.
  • DexCom made up 0.09% of 111 Capital's portfolio in Q2 2026, its #237 holding.
  • 111 Capital first reported a position in DexCom in Q1 2025 and has held it in 5 quarters since.
  • 111 Capital's DexCom position peaked at $1.75M in Q3 2025.
  • 968 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on 111 Capital's 13F filing for Q2 2026, filed 5 Aug 2026.